ScreenerHero

BCAB BioAtla, Inc.

Partial data
NAS · US · Healthcare · Biotechnology · bioatla.com
1.920USD+12.28%Mkt Cap: 3.20M $P/E: —

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotama…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.20M USD
Enterprise Value6.42M USD
Revenue (TTM)8.50M USD
Gross Profit-16.06M USD
Net Income (TTM)-59.61M USD
Revenue/Share6.14 USD
Last Price1.920 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.94
PEG—
EV/EBITDA-0.21
EV/Revenue0.76
P/S0.25
P/B-0.06
EPS (TTM)-24.30
EPS (Forward)-1.34
52W Range
1.0701% of range71.50
52W High71.50 USD
52W Low1.070 USD
Profitability
Gross Margin-188.92%
Oper. Margin3.49%
EBITDA Margin0.00%
Profit Margin-2980.35%
ROE164.71%
ROA-431.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-48.20M USD
CapEx (TTM)—
FCF Margin-139.54%
FCF Yield-370.77%
Net Debt4.32M USD
Net Debt/EBITDA-0.14
Balance Sheet
Debt/Equity-0.17
Current Ratio0.20
Quick Ratio0.17
Book Value/Sh-21.79 USD
Cash/Share0.93 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateApr 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.67M
Float1.39M
Insiders5.41%
Institutions21.37%
Short Interest
Short Ratio3.0d
Short % Float8.61%
Short % Out.8.34%
Shares Short138.89K
Short (prev mo.)123.94K
Technical
SMA 502.484 (-22.7%)
SMA 2008.227 (-76.7%)
Beta0.70
S&P 52W Chg13.94%
Avg Vol (30d)94.06K
Avg Vol (10d)19.37K
Technical Indicators
RSI (14)45.3
MACD-0.4426
MACD Signal-0.5129
MACD Hist.+0.0703
BB Upper3.639 USD
BB Middle1.952 USD
BB Lower0.2636 USD
BB Width172.99%
ATR (14)0.4427 USD
Vol Ratio (20d)0.02x